Montmorillonite nanodevices for the colon metronidazole delivery

Calabrese, Ilaria; Cavallaro, Gennara; Scialabba, Cinzia; Licciardi, Mariano; Merli, Marcello; Sciascia, Luciana; Liveri, Maria Liria Turco

doi:10.1016/j.ijpharm.2013.09.017

Cited by 73 publications

(44 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of nanoparticles as carriers for orally administered drugs targeted to the colon has also been reported previously (59)(60)(61). Studies have shown that these nanoparticulate systems improve the bioavailability of these drugs due to their increased surface area and thus increased contact with biological surfaces.…”

Section: Multiparticulate Systemsmentioning

confidence: 79%

“…To ensure a balance between efficiency, target-specificity, cost, and patient compliance, it appears that a combination of conventional and newer approaches is the key to the development of colon-specific drug delivery systems. In addition to the combined approaches, the exploration of nanotechnology seems to be an area of future research for colon targeting of drugs (59)(60)(61)83).…”

Section: Discussionmentioning

confidence: 99%

“…However, the nanoparticulate systems must be protected from being taken up by Payer's patches or degraded by enzymes before reaching the colon in order for this approach to be successful. Calabrese et al prepared nanotechnologybased hybrid formulations of metronidazole and K10-montmorillonite (MMT-K10) clay, and carried out kinetic and equilibrium studies to determine the release of MNE from this clay (60). The results showed that these newer nanoparticle formulations allowed for longer action in the colon.…”

Section: Multiparticulate Systemsmentioning

confidence: 99%

See 2 more Smart Citations

Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches

2015

View full text Add to dashboard Cite

Abstract. Colon-specific drug delivery systems (CDDS) are desirable for the treatment of a range of local diseases such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, chronic pancreatitis, and colonic cancer. In addition, the colon can be a potential site for the systemic absorption of several drugs to treat non-colonic conditions. Drugs such as proteins and peptides that are known to degrade in the extreme gastric pH, if delivered to the colon intact, can be systemically absorbed by colonic mucosa. In order to achieve effective therapeutic outcomes, it is imperative that the designed delivery system specifically targets the drugs into the colon. Several formulation approaches have been explored in the development colon-targeted drug delivery systems. These approaches involve the use of formulation components that interact with one or more aspects of gastrointestinal (GI) physiology, such as the difference in the pH along the GI tract, the presence of colonic microflora, and enzymes, to achieve colon targeting. This article highlights the factors influencing colon-specific drug delivery and colonic bioavailability, and the limitations associated with CDDS. Further, the review provides a systematic discussion of various conventional, as well as relatively newer formulation approaches/technologies currently being utilized for the development of CDDS.

show abstract

Section: Multiparticulate Systemsmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Multiparticulate Systemsmentioning

confidence: 99%

See 1 more Smart Citation

Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches

2015

View full text Add to dashboard Cite

show abstract

“…To understand the mechanisms involved, six standard models [30] applied to slow release systems were considered to describe the data. Within the error bars, our data can be well fitted by the zero order model [30].…”

Section: Chemical and Physical Characterization Of Samplesmentioning

confidence: 99%

Smectite as ciprofloxacin delivery system: Intercalation and temperature-controlled release properties

Rivera

Valdés

Jiménez

et al. 2016

Applied Clay Science

View full text Add to dashboard Cite

Ciprofloxacin (Cipro) incorporation into Li-fluorhectorite (LiFh) clay and its temperaturecontrolled release. with potential pharmaceutical and biomedical applications.Structural characterization of the raw material and the clay-drug composites.Demonstration of the temperature-controlled drug release abilities of a colloidal suspension of the clay-drug composite, following pharmaceutical standards. AbstractClays have shown to be good candidates as drug delivery carriers. In the present paper, we use the temperature-dependent swelling of smectite clays to produce clay-drug composites with sizable drug load capacity. Specifically, we obtain a fluorohectorite-ciprofloxacin (Fh-Cipro) composite, in which a true intercalation of the drug between the clay interlayers has been verified by various experimental techniques. We evaluate the thermally activated drug release from a colloidal suspension of nanosized composite particles in water as well as in synthetic gastric juice from 37 0 C (body temperature) to 85 0 C. The temporal profiles of drug release from the clay fulfil the pharmaceutical standards for these systems. In this work, we have been able to produce a clay-based Temperature Controlled Release System (TCRS) with potential biomedical applications.

show abstract

“…Very recently we have gauged the capability of a nanocomposite based on montmorillonite clay to deliver the antibiotic metronidazole [1]. Interestingly, the use of the new-tailor made formulation revealed to be very promising for prolonging the action of drug in the desired action site and also reducing both time and costs of preparation.…”

Section: Introductionmentioning

confidence: 99%